ifetroban Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Ifetroban is a potent and selective thromboxane receptor antagonist. It has been studied in animal models for the treatment of cancer metastasis, myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy, and for its effects on platelets. Clinical trials are evaluating the therapeutic safety and efficacy of oral ifetroban capsules for the treatment of cancer metastasis, cardiovascular disease, aspirin exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy.   Wikipedia

Chemistry

  • SMILES: CCCCCNC(=O)c1coc([C@H]2[C@@H](Cc3ccccc3CCC(=O)O)[C@@H]3CC[C@H]2O3)n1
  • InChIKey: BBPRUNPUJIUXSE-DXKRWKNPSA-N
  • Mol. Mass: 440.54
  • ALogP: 4.12
  • ChEMBL Molecules:
    ifetroban  
    ifetroban sodium  
More Chemistry

Pharmacology

Alternative names

benzenepropanoic acid, 2-((3-(4-((pentylamino)carbonyl)-2-oxazolyl)-7-oxabicyclo(2.2.1)hept-2-yl)methyl)-, (1s-(exo,exo))- | bms180291 | bms 180291 | bms-180291 | ifetroban

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (20)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (20)


 

Asthma (Phase 2)

Asthma, Aspirin-Induced (Phase 2)

Autoimmune Diseases (Phase 2)

Cardiomyopathy, Dilated (Phase 2)

Cardiovascular Diseases (Phase 2)

Connective Tissue Diseases (Phase 2)

Hepatorenal Syndrome (Phase 2)

Hypertension, Portal (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 2)

Liver Cirrhosis (Phase 2)

Lung Diseases (Phase 2)

Muscular Dystrophy, Duchenne (Phase 2)

Nasal Polyps (Phase 2)

Neoplasms (Phase 2)

Pathologic Processes (Phase 2)

Scleroderma, Diffuse (Phase 2)

Scleroderma, Limited (Phase 2)

Scleroderma, Systemic (Phase 2)

Skin Diseases (Phase 2)

Vascular Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 10
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue